As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...

Delve into the strategy of Viatris, a company that built its reputation around generics and is steadily moving beyond to find ...

As BIOSPAIN 2026 comes to end, delve into what as been at the center of this edition's discussion: what comes after we have ...

PMOS, formerly PCOS, still has no approved dedicated drug. Discover the new PMOS treatments in development, from GLP-1s to ...

Merck’s new BioReliance® Facility in Darmstadt, Germany, will support biologics testing, GMP release testing and stability ...

Brain biomarkers were long hard to pin down. See how new Parkinson's and Alzheimer's biomarkers are changing that.

Learn how to choose and integrate automated liquid handling solutions while overcoming challenges and supporting flexible lab ...

Look into Spain's biotech, an ecosystem that has matured and transforms promissing science into ventures but faces challenges ...

The companies ADARx Pharmaceuticals, Electra Therapeutics, and Enveda bagged the biggest biotech funding rounds overall in ...

September is often a strong month for the biopharma sector as the industry returns from the summer lull, keen on forging biotech deals.

Discover biotech and big pharma’s emerging interest in developing macrocyclic drugs for cardiometabolic diseases.

Two different antibody-drug conjugates (ADCs) targeting the same protein produced remarkably similar phase 3 results in relapsed small-cell lung cancer (SCLC) at WCLC 2026. Hansoh Pharma’s risvutatug ...